Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S ...Middle East

SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor...

Hence then, the article about bridge biotherapeutics announces initiation of phase 1 2 clinical trial of bbt 176 in egfr mutant nsclc with c797s was published today ( Wednesday 07/04/2021 - 01:17 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S )

Also on site :

• Emmylou Harris, Elvis Costello and More to Honor Country-Rock Legend With Special Show, 53 Years After He Died at Just 26
• Kroger and LG Sued for Allegedly Using Dog-Themed ‘Cheese Tax’ TikTok Song Without Licenses
• Bring a Burst of Cheer to Your Cooking With Aldi’s Sweet 2-Piece Kitchen Essential for Only $4